Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- AACR 2019 Research Roundup: Nanosensors for Cancer, New Immunotherapy Targets, a Road Map of Metastasis, and CAR T Fratricide on April 17, 2019 at 1:02 pm
Memorial Sloan Kettering scientists are presenting data from more than 100 studies at the American Association for Cancer Research’s 2019 annual meeting, held this year in Atlanta. Below is part two ... […]
- Immunotherapy Drugs Market is Anticipated to Cross US$ 289.52 Billion by 2024 on April 17, 2019 at 7:00 am
Apr 17, 2019 (Heraldkeeper via COMTEX) -- New York, April 17, 2019: Immunotherapy refers to treatments that stimulate, beautify or suppress the body’s personal immune system. Cancer segment is ... […]
- Iteos advancing adenosine antagonist as cancer immunotherapy in phase I/Ib on April 16, 2019 at 9:18 pm
LONDON - Iteos Therapeutics SA has joined the growing band of companies seeking to reverse tumor immune evasion by blocking the anti-inflammatory effects of adenosine signaling, with dosing of the ... […]
- UCSD patient gets first cancer treatment made from stem cells on April 16, 2019 at 7:58 am
A new form of cancer immunotherapy has been given to a University of California, San Diego Health patient in the first test of immune cells grown from stem cells. The patient, Derek Ruff ... […]
- Dr. Socinski on New Applications of Immunotherapy in NSCLC on April 15, 2019 at 1:38 pm
Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer (NSCLC). In ... […]
- Cancer Immunotherapy Market to attain a value of US$124.88 billion by 2024 - TMR on April 15, 2019 at 5:15 am
Albany, NY, Apr 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- Albany, NY, April 15, 2019 (GLOBE NEWSWIRE) -- According to TMR, the global cancer immunotherapy market is estimated to expand at a CAGR of 14.6 ... […]
- Cancer cells use tactics to avoid being recognised by immunotherapy agents on April 14, 2019 at 11:53 pm
Researchers have found that bowel cancer cells have a mechanism by which they can switch off some key molecules on their surfaces and thus escape being recognised and killed by the immunotherapy ... […]
- New Target for Cancer Immunotherapy: Exosomes on April 9, 2019 at 6:08 am
It was once a central tenet of biology that RNA molecules did their work inside the cell. But it’s now clear that RNA molecules are also active outside the cell, with potentially major implications ... […]
- Kidney cancer immunotherapy combo approved for NHS use in England on April 5, 2019 at 11:27 am
A combination of immunotherapy drugs will be made available to NHS patients with advanced and aggressive kidney cancer on the NHS in England. The decision to approve the treatment follows an ... […]
- Cancer Immunotherapy May Run Afoul of Exosomal Checkpoint Proteins on April 5, 2019 at 7:35 am
Checkpoint inhibition, a revolutionary cancer immunotherapy, works only in a minority of patients, and scientists want to know why it is resisted in the majority. At the UC San Francisco (UCSF), ... […]
via Bing News